GOQii has partnered with Acrannolife Genomics to launch the GrafCare Program, a groundbreaking initiative aimed at improving post-transplant care in India. This program integrates genomic diagnostics, artificial intelligence (AI), and personalized health monitoring to enhance patient outcomes.

Recognizing the critical need for proactive transplant care, GrafCare combines Acrannolife’s patented Trunome test with GOQii’s smart health ecosystem. The Trunome test, a non-invasive blood test, detects early signs of organ rejection or infection, enabling timely medical intervention. Patients also receive a GOQii Smart Vital Device, which continuously monitors key health metrics like heart rate, blood pressure, and oxygen levels. AI-driven analytics generate early alerts and tailored recommendations, ensuring proactive healthcare management.

GrafCare extends beyond monitoring by providing comprehensive support, including access to nutritionists and counselors who create personalized recovery plans based on the patient’s genetic and health data. To make this advanced care accessible, the program offers interest-free loans, discounts on immunosuppressants, and free diagnostic tests such as Tacrolimus and kidney/liver function tests.

GOQii’s Founder & CEO, Vishal Gondal, describes GrafCare as a lifeline for transplant recipients, leveraging AI and genomics to offer unprecedented care. Acrannolife’s Co-founder, Agragesh Ramani, emphasizes its mission to provide early detection and financial support, helping patients focus on recovery without additional stress.